Phaseline

Companies › Transcend Therapeutics

Transcend Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 3; Psychiatry; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TSND-201
MDMA-like empathogen (methylone analog)
–Phase 3Post Traumatic Stress DisorderDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07456696TSND-201Phase 3Post Traumatic Stress DisorderPsychiatryDec 2027
NCT07836647TSND-201Phase 3Post Traumatic Stress DisorderPsychiatryFeb 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Curemark Emalex Biosciences Boston Medical Group Gedeon Richter Cybin IRL

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.